Appraisement of 186/188Re-HEDP, a new compositional radiopharmaceutical
- 16 Downloads
Undoubtedly radionuclide therapy is the next phase of nuclear medicine development. 188Re-HEDP and 186Re-HEDP are therapeutic radiopharmaceuticals which have been used to treat bone metastases. With regard to their complementary features, in this study, as new idea their combined effects have been investigated with preparing the cocktail of 188/186Re-HEDP with radiochemical purity nearly 99%. The 188/186Re-HEDP biodistribution was checked in rats’ tissues up to 72 h. The produced 188/186Re-HEDP properties suggest a new bone palliative radiopharmaceutical to overcome bone metastases.
Keywords186/188Re-HEDP Combined radionuclide therapy Pain palliation Biodistribution
Compliance with ethical standards
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 3.Knapp FR, Dash A (eds) (2016) Introduction: radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine. In: Radiopharmaceuticals for therapy. Springer, Berlin, pp 3–23Google Scholar
- 9.Kothari K et al (1998) Preparation of 186Re complexes of dimercaptosuccinic acid and hydroxy ethylidine diphosphonate. Mod Trends Radiopharm Diagn Ther 29:539–555Google Scholar
- 20.Lyra M et al (2003) Radionuclide Therapy for Oncology – Current Status and Future Aspects, Rhenium-186-HEDP dosimetry and multiple bone metastases palliation therapy effects, Mediterra publishersGoogle Scholar
- 29.Zhi Y et al (2014) Preparation of 188Re-HEDP lyophilized kit for instant bone metastases therapy. Nucl Sci Tech 25(6):1–6Google Scholar